Pipeline

Precision immunotherapies against the entire universe of intracellular antigens

Peptide:HLA targets are found on all tumor types and several major auto-immune and infectious diseases. By exploiting antibody display technologies and advanced AI, we are building a diverse pipeline of best-in-class therapies engineered to have maximum potency with minimal toxicity.

Program

Indications

Differentiator

Discovery

Lead optimization

IND-enabling

ONCOLOGY

Neoantigen

IM810

P53 R175H

Breast, colon, pancreatic

Single digit nM affinity

Best-in-class specificity

IM41X

FLT3 D835Y

Acute Myeloid Leukaemia

First-in-class therapy

Best-in-class specificity

Shared

IM61X

undisclosed

Solid tumors

Novel target - checkpoint resistant tumors

IM62X

undisclosed

Solid tumors

Novel target - checkpoint resistant tumors

Our approach to peptide:HLA targeting

The Imuno TACTICS discovery platform allows us to obtain full control over how these therapies recognise and destroy diseased tissue. Already from the earliest stages of development, we can tune antibodies for both affinity and specificity, enabling us to develop highly potent yet safe therapies.